## **Trustees’ Annual Report for the period** ||**Period start date**|**Period start date**|**Period start date**|||**Period end date**|**Period end date**| |---|---|---|---|---|---|---|---| ||**Day**|**Month**|**Year**||**Day**|**Month**|**Year**| |**From**|23|June|2023|**To**|22|June|2024| ||||||||| |**Charity name**||||Radiotherapy UK|||| |**Other names charity is known by**||||ACCORN|||| |||||Action Radiotherapy|||| |**Charity registration number**||||1135902|||| ## **Objectives and Activities** ||SORP reference|| |---|---|---| |**Summary of the purposes of the**
**charity as set out in its governing**
**document**|Para 1.17|**1.**
**To promote, support and encourage research into**
**radiotherapy, radiobiology and allied subjects, and the**
**dissemination of the useful results of such research by**
**such actions as:**
a.
Promoting and facilitating multidisciplinary
collaboration between researchers and practitioners
in radiotherapy and its allied subjects
b.
Informing patients and the public about practice and
research in radiotherapy and its allied subjects, and
engaging patients and the public in the development
of research projects
c.
Awarding grants as appropriate
**2.**
**To advance and benefit the practice of radiotherapy and**
**its allied subjects to relieve sickness and preserve good**
**health by such actions as:**
a.
Promoting and facilitating multidisciplinary
networking and sharing of expertise and best
practice
b.
Promoting and encouraging the study of the science
and practice of radiotherapy and its allied subjects
c.
Promoting and facilitating increased involvement of
allied professions
d.
Facilitating development and dissemination of best
practices in radiotherapy and its allied subjects
e.
Disseminating knowledge concerning all aspects of
the science and practice of radiotherapy and its
allied subjects
f.
Promoting and facilitating education and training in
the research and practice of radiotherapy and its
allied subjects| |**Summary of the main actvites in**
**relaton to those purposes for the**
**public beneft, in partcular, the**
**actvites, projects or services**
**identfed in the accounts.**|Para 1.17 and
1.19|_1._
_Patent informaton resources_
We work to support patents with cancer through the
provision of trusted, accessible and relevant informaton
resources before, during and following their radiotherapy
treatment. We develop Patent Informaton Forum (PIF)
accredited resources that means patents and families can
trust that what we produce is evidence-based,
understandable, jargon-free, up-to-date and produced to the
best possible standard.
_2._
_Advocacy and Campaigning_
We work in partnership with patents, academics, workforce,
industry and parliamentarians to campaign for equality of
access to world-class radiotherapy for all patents with cancer
in the UK. We raise awareness of how harnessing
technologically advanced, cost-efectve radiotherapy could
treat more patents, quicker.
We are proud to be the charity partner of the
Radiotherapy4Life
campaign and
co-founder of the
#CatchUpWithCancer
campaign. As Secretariat for the APPG-
Radiotherapy we work with the Chair and Ofcers in
organising events, meetngs and ensuring all APPG regulatons
and requirements are met.
Our work also has global reach through our partnership with
the Global Coaliton for Radiotherapy as we support other
countries advocatng for increased access to radiotherapy
services.
_3._
_Workforce engagement and support_
Our work amplifes the voice of the frontline radiotherapy
workforce to raise awareness of the issues faced in the
delivery of services. We provide opportunites for the
workforce to learn and engage with ideas, innovatons and
technologies that can support them in developing patent-
centred care and practce. We ofer an actve network of
radiotherapy professionals who ofer peer support, educaton
and insight. We also promote careers in radiotherapy through
job listngs shared daily through our platorms and website.
_4.General fundraising/events_
The charity raises funds from a variety of sources including
online giving, community events, corporate partnerships,
individual donatons and grants. The charity was very grateful
to receive support in this fnancial year from B-Clear, Ergea,
Brainlab, Elekta, Varien-Siemens-Healthineers, FlenHealth,
Amethyst, AstraZeneca, Price-Jones, Accuray and Broyst
Foundaton.
_5. Research and Data_
The charity delivers analysis on publicly available data such as
waitng-tmes for cancer treatment and produces evidence-
based reports and research to beter understand how
radiotherapy services are currently being delivered and what
needs to change to improvepatent outcomes and| |---|---|---| |||experience.| |---|---|---| |**4**|Para 1.18|Radiotherapy UK has had regard to the guidance issued by the
Charity Commission on public beneft.
Radiotherapy UK is commited to making available to the
public, informaton regarding radiotherapy treatment and its
benefts, providing opportunites for radiotherapy
professionals to share informaton as well as campaign for
beter fundingfor radiotherapytreatment in the UK.| ## **Additional information (optional)** You may choose to include further statements where relevant about: ||Contributon made by volunteers|Para 1.38|Volunteers are essental to our charity's success in delivering
services. We depend on them to lead our organizaton
through the Board, and to guide our eforts via the
Ambassadors network, as well as patent and clinical
engagementgroups.|| |---|---|---|---|---| ## **Achievements and Performance** |**Achievements and Performance**|||| |---|---|---|---| ||SORP reference||| |Summary of the main
achievements of the charity,
identfying the diference the
charity’s work has made to the
circumstances of its benefciaries
and any wider benefts to society
as a whole.|Para 1.20||In additon to the actvites noted above
,the charity has
achieved the following this year for the beneft of patents,
professionals, and the wider community:
Advocacy and Policy

Development and delivery of landmark report from
the APPG-Radiotherapy; ‘World-class Radiotherapy
in the UK: Right Patent, Right Treatment, Right
Time
.’ The charity facilitated a UK-wide
collaboraton to deliver a 10-year vision for
radiotherapy that was launched in Parliament in
February 2025.

As part of our 10-year vision work, the charity
launched a patent survey to understand what
patents and family members thought world-class
radiotherapy would look like. We received 279
responses.

We atended two natonal conferences to amplify
the World-class Radiotherapy report, presentng at
the OPC in London and organising a ‘Big Hiter’
session at UKIO in London with patents and
workforce leading an engaging session.

The charity had our frst abstract poster accepted for
display at ESTRO 2024. Developed in partnership
with the Global Coaliton for Radiotherapy, the
poster highlighted the need for natonal and
internatonal advocacy to improve access to
radiotherapy. Poster can be viewedhere

Co-ordinated #CatchUpWithCancer day in parliament
for World Cancer Day 2024. Over 20 cancer charites
took part and over 60 MPs commited to working to
improve how long cancer patents wait for treatment
in the UK.

Actor, writer and comedian, Stephen Fry created a
video supportng our #CatchUpWithCancer
campaign, leading to an additonal 100,000
signatures on thechange.org petton
in one day and
bringingthe total amount of signatures to over| ||600,000.| |---|---| ||In partnership with Global Coaliton for Radiotherapy| ||organised ‘Integratng Radiotherapy into Cancer| ||Plans’ event at London Global Cancer Week.| ||Development, analysis and launch ofEquity of Access| ||report
found that 22% of the total populaton of the| ||UK are further than the recommended 45 minutes| ||from their closest radiotherapy service.| ||Radiotherapy UK contnues to act as secretariate to| ||the All-Party Parliamentary Group for Radiotherapy.| ||At the end of this period, the APPG had 57| ||members.| |Patent Informaton Resources|| ||Radiotherapy UK was awardedPIF TICK
accreditaton| ||to become a ‘trusted informaton creator’ with the| ||UK’s only assessed quality mark for print and online| ||health and care informaton| ||Coproducton of frstpatent‘virtual’video
to help| ||prepare patents for the experience of external beam| ||radiotherapy (EBRT) for breast cancer.| ||Coproducton and launch of new patent video series| ||‘Understanding Gamma Knife radiotherapy.
| ||Eight group and individual meetngs for partcipants| ||in our 2023 and 2024 Patent Engagement Groups| ||Ten patent and eleven clinical reviewers supportng| ||our patent informaton resource development| |Workforce Engagement|| ||Five RTUK Talks webinars, with total registratons of| ||843 and 1,291 views on YouTube. 2024 series| ||launched with aim of fve talks sponsored by| ||AstraZeneca.| ||Workforce Ambassadors programme re-launched| ||with 40 ambassadors in total engaged (16 from| ||relaunch)| ||Flash Workforce Survey 2023 launched. 803| ||Responses (over 10% of the Radiotherapy| ||workforce) to inform and support the advocacy work| ||of the charity in amplifying the voice of the frontline| ||workforce.| ||Ofcial communicaton channel established with| ||radiotherapy department managers via managers| ||network chairperson.| |Communicatons and Awareness|| ||The charity has a high media profle with regular| ||press coverage on natonal news and major print| ||publicatons. This year we also reached an| ||internatonal audience following the news of the| ||Princess of Wales’ diagnosis with our chair features| ||in ABC News, PBS and the Washington Post. All| ||coverage can be found here
.| |In line with our communicatons strategy, key social and|| |media channels have developed strongly over the course of|| |this year:|| ||**LinkedIn**: 75.6% followergrowth from 3,732 to| ||6,554.| |---|---| ||**Radiotherapy UK website**: 40,000 new users.| ||**YouTube**: 11,015 views, 492 watch hours, 83 new| ||subscribers (176% increase)| ||**Radiotherapy Daily newsleter**: Subscribers have| ||grown steadily to 1,887 from 1,808. 1,498| ||**Instagram**: grown from 2,402 followers to 2,538| ||followers. (5.66% growth)| ||**Facebook**: grown to 2,349 followers from 2,213.| ||(6.15% growth)| ||**X**: Analytcs now a paid-for service which we cannot| ||justfy as a small charity. We are also reviewing| ||whether we wish to contnue with this platorm.| ## Additional information (optional) You may choose to include further statements where relevant about: |
Achievements against objectves
set|
Para 1.41|
N/A| |---|---|---| |Performance of fundraising
actvites against objectves set|Para 1.41|N/A| |Other||Corporate Partnerships
The charity benefts from a number of corporate partnerships
for example Varian (Siemens Healthineers) and Ergea co-
sponsor the charity’s Daily News bulletn. All these
partnerships are agreed on a vendor neutral basis.| ## **Financial Review** |Review of the charity’s fnancial
positon at the end of the period|Para 1.21|The Charity’s total income for this fnancial year was £117,109
Total expenditure for this year was £162,760 leaving the
charity with a year-end net defcit of £45,651
During 2023/2024 The Charity has managed to contnue its
work within its limited budget by using its contacts and
generous donatons in kind (resources) from Price Jones Ltd.
With the current economic constraints and cost of living crisis
this is a challenging tme for charity income generaton.
However the charity are confdent that there are untapped
avenues of funding available to the organisaton. To support
accessing these, the charity will hire a part-tme fundraiser in
FY24-25.| |---|---|---| |Statement explainingthepolicyfor|Para 1.22|RadiotherapyUK’spolicyis toprovide the charitywith| |holding reserves statng why they
are held||adequate fnancial stability and the means for it to meet its
charitable objectves. Except for such funds as the Trustees
consider prudent to maintain for the purposes of
management and administraton of the charity for the
foreseeable future, all unrestricted funds are used to the
purpose of general objects of the charity. The adequacy of the
reserves is reviewed annually.| |---|---|---| |Amount of reserves held|Para 1.22|£150,624 (excluding the related party loan mentoned below)| |Details of fund materially in defcit|Para 1.24|The Charity has a long-term interest-free loan from related
party Price Jones Ltd which is repayable at £2,500pa. The
balance at June 2024 is £15,172| |Explanaton of any uncertaintes
about the charity contnuing as a
goingconcern|Para 1.23|There are no current uncertaintes regarding the charity
contnuing as a going concern.| |**Additional information (optional)**
You may choose to include further statements where relevant about:||| |The charity’s principal sources of
funds (including any fundraising)|Para 1.47|The Charity’s main source of funds for this reportng period
were:
1.
Public Donatons via online giving and community events.
2.
Corporate donatons from: BClear, Ergea, Brainlab,
FlenHealth, Varian Siemens-Healthineers, Amethyst,
AstraZeneca, Elekta, Price Jones, Accuray.
3.
Radiotherapy4Life donaton for administratve and
research analysis support.| |Investment policy and objectves
including any social investment
policyadopted|Para 1.46|We do not currently hold enough reserves to warrant an
investment policy.| |||| |A descripton of the principal risks
facing the charity|Para 1.46|**Current Challenges**
1.
Matching growth of charity to meet service development
needs with fnancial constraints
2.
Strained fnancial environment and COL crisis creates
difcult circumstances for fundraising
3.
Ensuring patents and benefciaries engaged with services
and organisatonal development.
4.
Developing appropriate governance structures in line
with organisatonal growth.
5.
Changing politcal environment
6.
Contnuing crisis in delivery of cancer services
exacerbated by workforce strikes, over-bureaucracy,
limitng leadership and minimal investment.| 1. ||Other||**Future initatves**
The following are considered to be priorites for the coming
year:
1.Implement fnal year of current strategic plan and begin
development of 2025 - 2028 strategy.
2.Recruit new Board members.
3.Development of detailed solutons following on from
Radiotherapy Vision 2024
4.Launch of new online patent informaton hub
5.Recruitment of Relatonship Fundraiser Manager to develop
income generaton avenues.
6.Expand workforce engagement initatves.
7.Contnue to campaign and advocate for increased access to
high quality radiotherapy services across the UK|| |---|---|---|---|---| |||||| ## **Structure, Governance and Management** |**Descripton of charity’s trusts:**||| |---|---|---| |**Type of governing document**
**(trust deed, royal charter)**|Para 1.25|Consttuton| |**How is the charity consttuted?**
**(e.g. unincorporated associaton,**
**CIO)**|Para 1.25|Associaton| |**Trustee selecton methods**
**including details of any**
**consttutonal provisions e.g.**
**electon to post or name of any**
**person or body enttled to**
**appoint one or more trustees**|Para 1.25|Original Trustees were nominated and elected by the
ACORRN Scientfc Steering Commitee. New Trustees are
nominated by the same process and are elected by
consensus of the Board of Trustees of Radiotherapy UK.| ## **Reference and Administrative details** |Charityname|RadiotherapyUK(previouslyActon Radiotherapy)| |---|---| |Other name the charityuses|ACORRN| |Registered charitynumber|1135902| |Charity’s principal address|4 Abbotsbury House
139 Abbotsbury Road
London W14 8EN| ## **Names of the charity trustees who manage the charity** |1
2
3
4
5
6|**Trustee name**|**Ofce (if any)**|**Dates acted if not**
**for whole year**| |---|---|---|---| ||Professor Patricia Price|Chair|| ||Dr Christy Goldsmith|Secretary|| ||Ms Tanya Levine|Treasurer|| ||Dr Clive Harmer||| ||Professor Philip Mayles||| ||||| ## **Funds held as custodian trustees on behalf of others** |Descripton of the assets held in
this capacity|None| |---|---| |Name and objects of the charity on
whose behalf the assets are held
and how this falls within the
custodian charity’s objects|None| |Details of arrangements for safe
custody and segregaton of such
assets from the charity’s own
assets|None| ## **Additional information (optional)** **Names and addresses of advisers (Optional information)** **Type of adviser Name Address** **Name of chief executive or names of senior staff members (Optional information)** Sarah Quinlan – Charity Director ## **Exemptions from disclosure** Reason for non-disclosure of key personnel details **Other optional information** ~~OS So~~ **Declarations The trustees declare that they have approved the trustees’ report above. Signed on behalf of the charity’s trustees Signature(s) Full name(s)** Professor Pat Price ~~i Ee~~ **Position (e.g. Secretary, Chair, etc** Chair **Date** ~~———~~ |**Radiotherapy UK**|||**1135902**||| |---|---|---|---|---|---| |**Receipts andpayments accounts**|||||**CC16a**| |**For the period**
**from**|23.06.2023|**To**|22.06.2024||| ## **Section A Receipts and payments** ||||**Unrestricted**
**funds**||**Restricted**
**funds**|**Restricted**||**Endowment**
**funds**||**Total funds**||**Last year**| |---|---|---|---|---|---|---|---|---|---|---|---|---| ||||**to the nearest**
**£**|**to the nearest**|**to the nearest £**|**to the nearest £**||**to the nearest £**||**to the nearest £**||**to the nearest £**| |**A1 Receipts**||||||||||||| |Corporate donations|||**91,431**||**-**|**-**||**-**||**91,431**||**74,822**| |Community|||**23,208**||**-**|**-**||**-**||**23,208**||**21,752**| |Trusts & Foundations|||**2,470**||**-**|**-**||**-**||**2,470**||**32,000**| ||||**-**||**-**|**-**||**-**||**-**||**-**| ||||**-**||**-**|**-**||**-**||**-**||**-**| ||||**-**||**-**|**-**||**-**||**-**||**-**| ||||**-**||**-**|**-**||**-**||**-**||**-**| ||||**-**||**-**|**-**||**-**||**-**||**-**| |**_Sub total_**_(Gross income for_
_AR)_||_(Gross income for_
_AR)_|**117,109**
_(Gross income for_||**-**|**-**||**-**||**117,109**||**128,574**| |**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**_Sub total_ -**
**-**
**-**
**-**
**-**
**_Total receipts_ 117,109**
**-**
**-**
**117,109**
**128,574**
**A2 Asset and investment**
**sales, (see table).**
~~—————=~~||||||||||||| |**A3 Payments**||||||||||||| |Advocacy& campaigning|||**11,537**||**-**|**-**||**-**||**11,537**||**2,387**| |Charityrunningcosts|||**5,626**||**-**|**-**||**-**||**5,626**||**2,960**| |Communications|||**8,318**||**-**|**-**||**-**||**8,318**||**6,909**| |Contractors|||**60,127**||**-**|**-**||**-**||**60,127**||**82,042**| |Incomegeneration|||**1,409**||**-**|**-**||**-**||**1,409**||**3,539**| |IT & development|||**5,734**||**-**|**-**||**-**||**5,734**||**4,335**| |Patient services|||**629**||**-**|**-**||**-**||**629**||**500**| |Professional fees|||**3,708**||**-**|**-**||**-**||**3,708**||**2,415**| |Promotional materials|||**823**||**-**|**-**||**-**||**823**||**42**| |Research & Data analytics|||**7,200**||**-**|**-**||**-**||**7,200**||**-**| |Salaries|||**53,617**||**-**|**-**||**-**||**53,617**||**3,836**| |Workforce services|||**255**||**-**|**-**||**-**||**255**||**391**| |Training& development|||**30**||**-**|**-**||**-**||**30**||**-**| |Loan repayment|||**2,500**||**-**|**-**||**-**||**2,500**||**2,500**| |||||||||||||| |**_Sub total_ **|||**161,513**||**-**|**-**||**-**||**161,513**||**111,856**| |Computer equipment
**1,247**
**-**
**-**
**1,247**
**1,056**
**-**
**-**
**-**
**-**
**_Sub total_ 1,247**
**-**
**-**
**1,247**
**1,056**
**_Total payments_ 162,760**
**-**
**-**
**162,760**
**112,912**
**_Net of receipts/(payments)_ - 45,651**
**-**
**-**
**- 45,651**
**15,661**
**A5 Transfers between funds**
**-**
**-**
**-**
**-**
**-**
**A6 Cash funds last year end**
**196,275**
**-**
**-**
**196,275**
**180,614**
**_Cash funds this year end_ 150,624**
**-**
**-**
**150,624**
**196,275**
**A4 Asset and investment**
**purchases, (see table)**
~~——————~~
~~===>>=>~~||||||||||||| ## **Section B Statement of assets and liabilities at the end of the period** |**Categories**
**B1 Cash funds**
**B2 Other monetary assets**
**B3 Investment assets**
**B5 Liabilities**
**B4 Assets retained for the**
**charity’s own use**
Signed by one or two trustees on
behalf of all the trustees|**Details**
Bank
**Details**
**Details**
**Details**
**Details**
Signature
**_Total cash funds_**
(agree balances with receipts and payments
account(s))
Loan due to Professor Pat Price
Limited|**to nearest £**
**Unrestricted**
**funds**|**to nearest £**
**Unrestricted**
**funds**| |---|---|---|---| |||**150,624**|**-**| |||**-**|**-**| |||**-**|**-**| |||**150,624**|**-**| |||OK
**to nearest £**
**Unrestricted**
**funds**|| |||**-**|**-**| |||**-**|**-**| |||**-**|**-**| |||**-**|**-**| |||**-**|**-**| |||**-**|**-**| |||**Fund to which**
**asset belongs**|| ||||**-**| ||||**-**| ||||**-**| ||||**-**| ||||**-**| |||**Fund to which**
**asset belongs**|| ||||**-**| ||||**-**| ||||**-**| ||||**-**| ||||**-**| ||||**-**| ||||**-**| ||||**-**| ||||**-**| |||**Fund to which**
**liability relates**|| ||||**15,172**| ||||**-**| ||||**-**| ||||**-**| ||||**-**| ||||| ||||| ## **Trial Balance** ## Radiotherapy UK As at 22 June 2024 Cash Basis |**Account Code**|**Account**|**Account Type**| |---|---|---| |208|OnlinePlatforms: Amazon|Sales| |218|Events: CharityAppeals(e.g. Xmas)|Sales| |226|Corporate Donations|Sales| |227|Community|Sales| |234|Online Platforms: Just Giving|Sales| |236|Events: Miles4Radiotherapy|Sales| |240|Online Platforms(all)|Sales| |242|Sales of Product Income|Sales| |244|Services|Sales| |246|Online Platforms: Stripe|Sales| |248|Trusts &Foundations|Sales| |400|Professional fees: Accounting|Overhead| |402|IT&Development: AccountsManagement (Xero/QB)|Overhead| |404|Advocacy& Campaigning (R4L)|Overhead| |406|Professional fees: Bank Fees|Overhead| |412|CharityRunning Costs: Entertaining|Overhead| |414|Contractors: Comms Support|Overhead| |418|Contractors:Communications Officer|Overhead| |424|Contractors(all)|Overhead| |425|Contractors(GCR)|Overhead| |426|Communications: Coordination Platform|Overhead| |430|Communications: DailyNews|Overhead| |432|Contractors: Director|Overhead| |434|CharityRunningCosts: Equipment|Overhead| |436|Income Generation: Events|Overhead| |438|Income Generation: Design work(non campaign)|Overhead| |442|Professional fees: HR/Recruitment|Overhead| |446|PatientServices|Overhead| |448|Professional fees: Insurance|Overhead| |452|Interest Payable|Overhead| |454|Contractors: Internship|Overhead| |456|IT & Development|Overhead| |458|IT & Development: IT Support|Overhead| |464|Professional fees: Licencing|Overhead| |466|IT&Development: MarketingPlatform|Overhead| |468|Professional fees: Memberships|Overhead| |472|IT&Development: Monitoring &Evaluation Tools (SurveyMonkey)|Overhead| |480|Research & Data Analysis|Overhead| |481|Training& Development(RTUK team)|Overhead| |490|Communications: Photography/Video production|Overhead| |492|Income Generation: Platform Fees|Overhead| |494|CharityRunning Costs: Postage|Overhead| |495|CharityRunningCosts: Stationery|Overhead| |500|Contractors: Project Manager|Overhead| |504|Promotional Materials|Overhead| |522|Salaries(inc.payeepension contributions)|Overhead| |523|Salaries: Employerpensioncontributions|Overhead| |526|IT & Development: Software|Overhead| |530|CharityRunning Costs: Travel/Accommodation|Overhead| |538|Workforce Services: Video Conference Tools|Overhead| |540|IT & Development: Website Hosting|Overhead| |542|IT&Development: WebsiteMaintenance|Overhead| |544|Communications: Website Design Projects|Overhead| |552|Workforce Services:Other|Overhead| |806|Loan Repayments: Loan from PJ Ltd|Current Liability| |600|Current|Bank| |602|Equals Account|Bank| |606|Savings|Bank| |610/1|Debtors|Current Asset| |820|VAT|Current Liability| |---|---|---| |902|OpeningBalance Equity|Equity| |960|Retained Earnings|Equity| |**Total**||| |**Debit - Year to date**
**Credit - Year to date**
**Category**
**22Jun 2023**|**Debit - Year to date**
**Credit - Year to date**
**Category**
**22Jun 2023**| |---|---| |0.00
Community
(35.85)|| |0.00
Community
49.00|| |91,430.74
Corporate Donations
(104,821.68)|| |5,014.25
Community
0.00|| |0.00
Community
(8,099.30)|| |517.86
Community
(12,584.87)|| |17,676.21
Community
(682.97)|| |0.00
Community
(247.75)|| |0.00
Community
(51.49)|| |0.00
Community
(44.30)|| |2,470.46
Trusts &Foundations
(2,000.00)|| |1,991.24
Professional fees|936.00| |271.40
IT& development|244.80| |11,537.81
Advocacy& campaigning|2,386.76| |84.60
Professional fees|90.00| |0.00
Charityrunning costs|71.40| |0.00
Contractors|900.00| |0.00
Contractors|2,116.00| |55,655.25
Contractors|2,700.00| |680.00
Contractors|0.00| |292.80
Communications|221.90| |5,000.00
Communications|4,287.50| |3,791.71
Contractors|46,667.20| |1,247.21
Charityrunningcosts|1,056.29| |1,408.55
Income generation|2,523.96| |0.00
Incomegeneration|1,040.00| |600.00
Professional fees|444.00| |628.60
Patientservices|500.00| |268.59
Professional fees
0.00
Interestpayable|259.60| ||(0.04)| |0.00
Contractors|4,383.46| |22.40
IT & development|690.26| |0.00
IT & development|374.37| |625.56
Professional fees|650.60| |1,030.34
IT& development|628.90| |138.09
Professional fees|35.00| |384.00
IT& development|384.00| |7,200.00
Research & Data Analysis|0.00| |30.00
Training& Development(RT
0.00|| |2,400.00
Communications
327.99|| |216.00
Charityrunningcosts
251.99|| |332.44
Charityrunning costs
89.29|| |43.52
Charityrunningcosts
0.00|| |0.00
Contractors
25,662.50|| |822.53
Promotional materials
42.00|| |51,434.64
Salaries
3,835.68|| |2,182.19
Salaries
0.00|| |4,013.94
IT & development
1,635.07|| |5,033.88
Charityrunning costs
2,460.57|| |235.08
Workforce services
225.50|| |0.00
IT & development
341.84|| |13.26
IT& development
35.99|| |625.00
Communications
1,700.00|| |19.48
Workforce services
150.00|| |2500
0.00 Loan
(17,672.00)|| |46022.47 Bank
195,629.73|| |366.83
Bank
659.80|| |5.05
Bank
0.00|| |0.00
(106.30)|| |434.50||0.00| |---|---|---| |||(147,200.71)| |||(13,141.69)| |**163,566.49**|**163,131.99**|**(0.00)**| ||Data|| |---|---|---| |Category|Sum of Debit - Year to date
Sum of Credit - Year to date|| |Advocacy & campaigning
Charity running costs
Communications
Community
Contractors
Corporate Donations
Income generation
Interest payable
IT & development
Loan
Patient services
Professional fees
Promotional materials
Research & Data Analysis
Salaries
Training & Development (RTUK team)
Trusts & Foundations
Workforce services|11,537.81
6,873.05
8,317.80
23,208.32
60,126.96
91,430.74
1,408.55
0.00
5,735.34
2,500.00
0.00
628.60
3,708.08
822.53
7,200.00
53,616.83
30.00
2,470.46
254.56|| |**Total Result**|**162,760.11**
**117,109.52**|| |Client:|Prepared by:|Date:|Ref:
**A2.2**| |---|---|---|---| |Year End:|Reviewed by:|Date:|| |File Number:|||| ## **UNCORRECTED MISSTATEMENTS** _Only those misstatements that are not regarded as clearly trivial should be recorded on this schedule. When considering whether a misstatement is material the auditor should consider size, nature and circumstances._ ## **Final materiality:** ## **Considered clearly trivial if below:** |**_Narrative_**|**_Narrative_**|**_Extrapolated_**
**_misstatements_**|**_Extrapolated_**
**_misstatements_**|**_Actual misstatements_**|**_Actual misstatements_**|**_Profit and_**
**_loss_**|**_Balance_**
**_sheet_**| |---|---|---|---|---|---|---|---| |||**_DR_**|**_CR_**|**_DR_**|**_CR_**||| ||||||||| ||||||||| ||||||||| ||||||||| ||||||||| ||||||||| ||||||||| ||||||||| ||||||||| ||||||||| ||||||||| ||||||||| ||||||||| ||||||||| ||||||||| ||||||||| ||||||||| ||||||||| ||||||||| ||||||||| ||||||||| ||||||||| |Total of potential adjustments||-|-|-|-|-|-| ## **Conclusion** 1. The client has been asked to adjust for all misstatements noted above. 2. Where the client has not adjusted for misstatements drawn to their attention, the letter of representation explains the directors’ reasons for not adjusting as required by ISA 450.14. 3. None of the potential adjustments listed above are considered to be indicative of fraud. 4. None of the potential adjustments listed above individually or in total indicate that the overall strategy and audit plan need to be revised. 5. Croner-i Audit - October 2018 Page 8 of 9 B7 B7 Page9of9 Croner-i Audit - October 2018 ## **Independent Examiner's Report to the Trustees of Radiotherapy UK** I report to the trustees on my examination of the accounts of Radiotherapy UK for the year ended 22 June 2024. ## **Responsibilities and basis of report** As the charity trustees you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011. (‘the Act’). I report in respect of my examination of the Trust’s accounts carried out under section 145 of the 2011 Act and in carrying out my examination I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the Act. ## **Independent examiner’s statement** I have completed my examination. I confirm that no material matters have come to my attention in connection with the examination giving me cause to believe that in any material respect: 1. Accounting records were not kept in respect of the Trust as required by section 130 of the Act; or 2. The accounts do not accord with those records. I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report to enable a proper understanding of the accounts to be reached. Susan Redmond FCA DJH Limited Chartered Accountants St George's House 56 Peter Street Manchester M2 3NQ 20[th] December 2024 ## **RADIOTHERAPY UK YEAR ENDED 22 JUNE 2024 NOTES TO ACCOUNTS** ## **Interest-free loan** The charity received an interest-free loan from Price Jones Limited, a company in which one of the trustees Professor Patricia Price is a director and shareholder. The loan currently stands at £15,172 and is repayable at £2,500 per annum beginning 1 July 2017. ## **Related party transactions** During the year there was a further £4,676 (2023: £2,462) paid to Professor Pat Price Limited. These were for general administrative costs, and costs relating to the All Party Parliamentary Group for Radiotherapy. All transactions were considered to be at arm’s length. During the year donations of £40,000 (2023:£44,083) were received from Radiotherapy4Life Limited, a company in which one of the trustees Patricia Price is a director and shareholder. Donations of £5,000 were received from Professor Pat Price Limited, a company in which Patricia Price is also a director.